Log in

NASDAQ:RETA - Reata Pharmaceuticals Stock Price, Forecast & News

$211.43
-4.84 (-2.24 %)
(As of 01/21/2020 03:12 AM ET)
Today's Range
$211.41
Now: $211.43
$220.59
50-Day Range
$199.15
MA: $207.28
$217.74
52-Week Range
$70.00
Now: $211.43
$224.02
Volume224,928 shs
Average Volume275,805 shs
Market Capitalization$6.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.58
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.59 million
Book Value$0.51 per share

Profitability

Net Income$-80,550,000.00
Net Margins-398.84%

Miscellaneous

Employees123
Market Cap$6.40 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive RETA News and Ratings via Email

Sign-up to receive the latest news and ratings for RETA and its competitors with MarketBeat's FREE daily newsletter.


Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals Inc (NASDAQ:RETA) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.25) by $0.07. The business earned $8.24 million during the quarter, compared to analyst estimates of $7.43 million. Reata Pharmaceuticals had a negative net margin of 398.84% and a negative return on equity of 3,281.61%. The company's revenue for the quarter was up 59.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.07) earnings per share. View Reata Pharmaceuticals' Earnings History.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Reata Pharmaceuticals.

What price target have analysts set for RETA?

8 equities research analysts have issued 12-month target prices for Reata Pharmaceuticals' stock. Their forecasts range from $130.00 to $328.00. On average, they anticipate Reata Pharmaceuticals' share price to reach $255.63 in the next twelve months. This suggests a possible upside of 20.9% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.

What is the consensus analysts' recommendation for Reata Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.

What are Wall Street analysts saying about Reata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (12/11/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 PT on RETA. Reata reported 4Q18 financial performance including collaboration revs of $7.9M, total expenses of $130.5M and cash of $338M. We project current cash to be sufficient to fund operations through 2020, including the three ongoing pivotal trials of bardoxalone in Alport syndrome and CTD-PAH, and omaveloxolone in Friedreich’s ataxia. We see 2019 as a potentially transformational year for the company, with two pivotal trial readouts in the second half and increasing visibility on a broadening set of bard’ indications going forward to further drive shares." (2/28/2019)

Has Reata Pharmaceuticals been receiving favorable news coverage?

News articles about RETA stock have been trending negative recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Reata Pharmaceuticals earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Reata Pharmaceuticals.

Who are some of Reata Pharmaceuticals' key competitors?

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), First Financial Bankshares (FFIN), Precision Drilling (PDS), Synlogic (SYBX), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Archrock (AROC), Targa Resources (TRGP), Precision Drilling (PD) and Gilead Sciences (GILD).

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the folowing people:
  • Mr. J. Warren Huff, Chairman, CEO & Pres (Age 65)
  • Dr. Colin J. Meyer, Chief Medical Officer & Exec. VP of Product Devel. (Age 40)
  • Dr. Keith W. Ward, Consultant (Age 49)
  • Mr. Jason D. Wilson, CFO & Exec. VP of Strategy (Age 49)
  • Ms. Elaine Castellanos, VP of Fin. & Accounting

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.12%), Woodstock Corp (0.05%), Penn Davis Mcfarland Inc. (0.02%), Tocqueville Asset Management L.P. (0.01%), Zeke Capital Advisors LLC (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Reata Pharmaceuticals stock include Cpmg Inc, Elaine Castellanos, James Edward Bass, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Institutional Ownership Trends for Reata Pharmaceuticals.

Which major investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Woodstock Corp, Tocqueville Asset Management L.P. and Nisa Investment Advisors LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos, James Edward Bass, James Warren Huff, Jason Douglas Wilson and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.

Which major investors are buying Reata Pharmaceuticals stock?

RETA stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Penn Davis Mcfarland Inc. and Zeke Capital Advisors LLC. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, James Edward Bass and James W Traweek Jr. View Insider Buying and Selling for Reata Pharmaceuticals.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $211.43.

How big of a company is Reata Pharmaceuticals?

Reata Pharmaceuticals has a market capitalization of $6.40 billion and generates $53.59 million in revenue each year. The company earns $-80,550,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis. Reata Pharmaceuticals employs 123 workers across the globe.View Additional Information About Reata Pharmaceuticals.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is http://www.reatapharma.com/.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]


MarketBeat Community Rating for Reata Pharmaceuticals (NASDAQ RETA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  568
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel